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MinireviewParkin and the Molecular Pathways
of Parkinson’s Disease
led to phenomenal progression in the characterization
of Lewy pathology. -syn is a small (140 amino acid)
protein characterized by repetitive imperfect repeats
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(KTKEGV) distributed throughout most of the amino-University of Pennsylvania School of Medicine
terminal half of the polypeptide, a hydrophobic middlePhiladelphia, Pennsylvania 19104
region (NAC region), and an acidic carboxy-terminal re-
gion (Figure 1A). The function of -syn is not clearly
established, but it appears to have some role in the
Parkinson’s disease (PD) is a neurodegenerative dis- modulation of synaptic vesicle turnover and synaptic
ease characterized by the selective demise of specific plasticity (Clayton and George, 1998). -syn has the
neuronal populations leading to impairment of motor ability to polymerize into 10 nm fibrils in vitro, and
functions. Recent genetic studies have uncovered bundles of these fibrils are the major components of
several genes involved in inherited forms of the dis- LBs and LNs (Figure 1B). The A53T mutation in -syn
ease. These gene products are implicated in the bio- results from a G to A transition at position 209 and
chemical pathways underlying the etiology of sporadic follows an autosomal dominant mode of transmission
PD. Mutations in the parkin gene causal of autosomal (Polymeropoulos et al., 1997). The pathological conse-
recessive juvenile parkinsonism highlight that ubiqui- quences of this mutation appear to stem from a sig-
tin-mediated proteolysis may play an important role nificant increase in its propensity to polymerize. Fur-
in the pathobiology of PD. thermore, transgenic mouse and Drosophila models
overexpressing -syn suggest that the formation of
-syn inclusions can lead to neuronal dysfunction andIntroduction
other phenotypes reminiscent of human disorders (Daw-Parkinson’s disease (PD) is the most common move-
son, 2000).ment disorder, with a prevalence of 1% at 65 years of
-syn pathology is not restricted to PD but rather isage but increasing to 4%–5% by the age of 85. It is
a prominent feature of a spectrum of diseases termedcharacterized clinically by bradykinesia (slowed move-
“-synucleinopathies” (Duda et al., 2000). In some ofment), resting tremor, rigidity, and postural instability.
these diseases such as dementia with LBs and LB vari-Although the neuronal circuitry involved in coordinated
ant of Alzheimer’s disease, Lewy pathology is broadlymovement is complex, the disabling symptoms of PD
distributed in the cerebrum. -syn aggregation can alsoare predominantly due to a profound reduction in striatal
occur in oligodendrocytes in the form of glial cyto-dopamine content caused by the demise of dopaminer-
plasmic inclusions, which are the major characteristicgic neurons in the substantial nigra (SN) pars compacta
features of multiple system atrophy.(Forno, 1996). The distinct pathological lesions of PD
Mutations in the Parkin Gene Are Causal ofare round eosinophilic inclusions, comprised of a halo
Autosomal Recessive Juvenile Parkinsonismof radiating fibrils and a less-defined core, known as
Autosomal recessive juvenile parkinsonism (AR-JP) is a“Lewy bodies” (LBs), and dystrophic neurites termed
disease entity that has been shown to result from the“Lewy neurites” (LNs) (Forno, 1996).
loss of function of the parkin gene (Kitada et al., 1998).The underlying cause(s) of most cases of PD is still
These patients display the typical clinical features ofunknown, but, recently, specific genetic defects have
parkinsonism, but they also often present with foot dys-been identified in several kindred. Although this review
tonia, benefit from sleep, and marked response to L-dopafocuses on these genes and their functions, we feel
therapy. Onset of this disease can be as early as thethat it is also important to highlight that environmental
first decade of life, but, for most cases, the onset is laterfactors, perhaps specific toxins, may contribute to the
than what could be considered “juvenile.” In fact, onsetdisease. In fact, Betarbet et al. recently reported that rats
is best described as before the age of 40, although somechronically challenged with rotenone, a plant-derived
rare cases can have onset as late as the sixth decadeinhibitor of mitochondrial complex I that is used as a
of life (Klein et al., 2000). Neuropathological examinationhousehold pesticide and in the control of fish popula-
demonstrates that neuronal loss and gliosis are re-tions, develop the behavioral and histological features
stricted to the SN and locus ceruleus (Hayashi et al.,
of PD (Betarbet et al., 2000). Furthermore, in both hu-
2000; Mori et al., 1998). In several cases, Lewy pathology
mans and animal models, oxidative stress is believed to
was not observed (Hayashi et al., 2000; Mori et al., 1998),
be involved in the selective vulnerability of dopaminergic leading to the speculation that the etiology of AR-JP
neurons of the SN due to their intrinsic predisposition differs significantly from PD. However, the recent au-
to generate reactive species. topsy of a patient with a 40 bp deletion in exon 3 in
-Synuclein Mutations and the Elucidation of the one allele of parkin and a R275W mutation in the other
Composition of Lewy Pathology revealed the presence of Lewy pathology in the typical
The identification of a mutation (A53T) in the gene en- regions affected in PD (Farrer et al., 2001).
coding the presynaptic protein -synuclein (-syn) in The parkin gene maps to chromosome 6q25.2-q27
several kindreds with PD (Polymeropoulos et al., 1997) and spans more than 500 kbp, and its 12 exons encode
a 465 amino acid protein (Kitada et al., 1998). Parkin
bears homology to ubiquitin at its N terminus, and two1Correspondence: vmylee@mail.med.upenn.edu
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Figure 1. -Synuclein Structure and Hypo-
thetical Model for Its Aggregation
(A) Schematic representation of -syn and
the mutations associated with familial PD.
(B) Polymerization of -syn resulting in the
formation of neuronal or glial inclusions.
RING finger motifs are separated by an in-between RING protein that is usually convalently linked to the  amino
group of Lys residues in the targeted proteins by thefingers (IBR) domain near the C terminus (Figure 2). The
most common parkin mutations are deletions of one or formation of an isopeptide with its C terminus. Targeting
to the proteasome usually requires the formation of aseveral exons, but duplications and triplications have
also been observed (Kitada et al., 1998; Lucking et al., polyubiquitin chain, where the C terminus of each ubi-
quitin is added to a specific Lys residue of the previous2000). Some of these deletions are predicted to result in
premature termination of translation due to frameshifts; ubiquitin. Ubiquitination is a tightly regulated process
that requires at least three steps: (1) formation of anhowever, the deletions of exon 5 or exon 3 plus exon 4
are in-frame deletions which are predicted to result in ATP-dependent thioester linkage between ubiquitin and
the activating enzyme, E1; (2) transfer of the anchoredthe expression of shorter proteins of 437 (deletion of
codons 179 to 206) and 344 (deletion of codons 58 to ubiquitin moiety to a ubiquitin-carrier protein, E2; and
(3) ubiquitination of the targeted protein by the E2/E3178) residues, respectively. Frameshift mutations re-
sulting from the insertion or deletion of one, two, or five complex. Target specificity is dictated by the functional
interaction between E3 and the substrate.base pairs (Lucking et al., 2000), nonsense mutations,
and missense mutations (Figure 2) are also causal to Many RING finger proteins (Joazeiro and Weissman,
2000), including parkin (Shimura et al., 2000; Zhang etdisease, but so far it appears that all mutations are
recessive. Mutations in the parkin gene have been found al., 2000), have been shown to act as E3 ligases. Parkin
can interact with the E2 ubiquitin-carrier proteins UbcH7on both alleles for the majority of patients with AR-JP.
In some rare cases, mutations were identified in only and UbcH8, resulting in functional ubiquitination (Figure
3). Similar to other E3 RING finger proteins (Joazeiroone allele (Lucking et al., 2000), but there is likely an
undetected complementary mutation in the other allele, and Weissman, 2000), the RING finger region of parkin
confers the binding site for E2s (Imai et al., 2000; Shimuraperhaps in the promoter or in an intron. The cluster
of mutations in the RING fingers and the IRB domain et al., 2000; Zhang et al., 2000). Mutations in parkin can
suggests that the preservation of these regions is impor-
tant for function.
Parkin Is an E3 Ligase
Recent findings have shed new light on the function of
RING finger proteins. Many of these proteins appear to
have a critical role in mediating the ubiquitination of
specific proteins, as well as themselves (Joazeiro and
Weissman, 2000). Ubiquitin tagging of membrane-
bound cytoplasmic and nuclear proteins identifies these
molecules as a target for degradation by the proteasome
and can also facilitate the endocytosis of plasma mem-
brane proteins to lysosomes for degradation (Hershko
and Ciechanover, 1998). Ubiquitin is a 76 amino acid
Figure 3. Involvement of Parkin in the Ubiquitin-Proteasome
Pathway
Parkin (E3) serves as a link between the substrate for ubiquitination
and E2s, which bind to the RING finger region. Alternate regions in
parkin may recognize different substrates. The ubiquitin-like region
Figure 2. Schematic Representation of the Parkin Protein is either required for the recruitment of an accessory protein or the
binding of some substrates that may include Sp22. Pael-R andParkin consists of several domains: an amino-terminal ubiquitin-like
domain (Ub-like) and two carboxy-terminal RING finger domains synphilin-1 interacts with the RING finger region, but synphilin-1
preferentially binds to the IBR region and the second RING fingerseparated by an IBR. The location of disease-related point mutations
resulting in amino acid substitutions or protein truncation is de- domain. Ubiquitin moieties are transferred from E1 to E2 and finally
to the substrate, which becomes a target for degradation by thepicted. Additional frameshift and deletion mutants have been de-
scribed; see text for details. proteasome.
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disrupt the interaction with E2s, and it can also impair its coexpression with -syn in cultured cells results in
the formation of aggregates containing both proteinssubstrate recognition. The AR-JP-associated mutations
Q311stop (resulting in a protein lacking the IRB and (Chung et al., 2001). In the presence of parkin, a signifi-
cant percentage of these aggregates become ubiquiti-second RING finger) or T240R abrogate the interaction
between parkin and UbcH7 (Shimura et al., 2000, 2001). nated.
Parkin may also have a role in the regulation of -synThe mutation R42P does not affect the interaction with
UbcH7 but still abolishes ubiquitination, suggesting that metabolism. It can exist in complex with UbcH7 and a
newly identified O-glycosylated isoform of -synit can disrupt the recruitment of a necessary accessory
protein or the binding of some substrates (Shimura et (Sp22) that contains complex monosaccharide chains
(Shimura et al., 2001). However, whether or not Sp22 isal., 2000, 2001). Interaction with UbcH8 is eliminated by
the Q311stop and T415N mutations, while the mutations present in brain is controversial, since most laboratories
have not been able to detect it, and this type of complexT240R and W453stop reduce binding (Zhang et al.,
2000). Seemingly at odds with the notion that the RING glycosylation is highly unusual for a cytoplasmic protein.
The specificity of parkin for glycosylated isoform of -syndomain region is the E2 binding site, the in-frame exon
3-4 deletion, which results in the ablation of codons 58 is very stringent, as nonglycosylated-syn is completely
inert to parkin (Shimura et al., 2001; Chung et al., 2001).to 178, prevents the interaction of parkin and UbcH7 or
UbcH8 (Imai et al., 2000). These results remain unex- Wild-type parkin can promote the ubiquitination of
Sp22, but the R42P and T240R mutants do not displayplained, but it is possible that the omission of this stretch
of residues results in a misfolded protein with a nonfunc- this activity. Although the abundance of Sp22 is ex-
tremely scarce in normal brain, it is found at modesttional binding site. Nevertheless, these results also dem-
onstrate that the exon 3-4 deletion mutant results in the levels in AR-JP brains lacking parkin activity (Shimura
et al., 2001). Shimara et al. proposed that ubiquitinationloss of E3 ligase activity. Like other E3 ligases (Joazeiro
and Weissman, 2000), parkin can induce its self-ubiquiti- of Sp22 may be a prerequisite in the formation of Lewy
pathology, since it was believed that AR-JP patients donation and degradation, and disease-associated muta-
tions in the RING finger domains also can impair these not have these inclusions. The recent report of an AR-
JP patient with LBs and LNs (Farrer et al., 2001) demon-properties (Imai et al., 2000; Zhang et al., 2000).
The activity of parkin as an E3 ligase and the impair- strates that some of these patients can develop these
inclusions, but the presence of Lewy pathology mayment thereof by pathological mutations suggests that
ubiquitination may be important in the etiology of PD. depend on the nature of the mutation. AR-JP patients
with homologous null mutations appear to have no LewyConsistent with this notion is the presence of ubiquitin
moieties in all types of -syn inclusions. Furthermore, inclusions (Hayashi et al., 2000), while the patient de-
scribed by Farrer et al. harbors a null mutation in onein two siblings with parkinsonism, a substitution (I93M)
was identified in ubiquitin carboxy-terminal hydrolase allele and a R275W mutation in the other. The latter
mutation reduces the catalytic activity of parkin, but itL1(UCHL-1), another enzyme involved in ubiquitin me-
tabolism (Leroy et al., 1998). Since this amino acid still has substantial enzyme activity (Chung et al., 2001).
Whether or not parkin is required for the formation ofchange or other substitutions in UCHL-1 has not been
identified in other families with PD, it is still not entirely Lewy pathology remains speculative, and further patho-
logical examinations of additional patients with parkinclear if the I93M substitution is a dominant mutation
causal of disease or an extremely rare variant that co- mutations will be required to resolve this issue.
We propose that Lewy pathology might contribute tosegregates with disease. This uncertainty notwithstand-
ing, the mutation I93M in UCHL-1 results in a partial loss neuronal cell death by the sequestration of functional
parkin, which serves to degrade specific proteins. Theof catalytic activity (Leroy et al., 1998). UCHs constitute a
large family of deubiquitinating enzymes that can cleave inability to remove these proteins can eventually lead to
toxicity. Indeed, evidence to support this notion includespolymeric ubiquitin into monomers. These enzymes may
reduce the ubiquitin-tagged degradation of specific pro- the detection of parkin in LBs (Shimura et al., 2001) and
its accumulation into inclusions comprised of -syn andteins, and they can be important for the regeneration of
free and reusable ubiquitin following protein degrada- synphilin-1 in cultured cells (Chung et al., 2001). It is
possible that the attempt of parkin to target these inclu-tion (Hershko and Ciechanover, 1998).
Parkin Substrates and Possible sions for degradation results in its loss of function. This
model is consistent with the finding that patients withDisease Mechanisms
Zhang et al. demonstrated that parkin interacts with null mutations in parkin do not require Lewy pathology
for disease, whereas Lewy pathology is present in theand promotes the ubiquitination of the synaptic vesicle-
associated protein CDCrel-1 (Zhang et al., 2000). Parkin patient with the R275W mutation. Moreover, the reduc-
tion in parkin activity can contribute to inclusion forma-increases the degradation of CDCrel-1, while the muta-
tions Q311stop and T415N do not affect turnover. tion, since synphilin-1, which may induce the formation
of -syn aggregates, is a substrate for parkin and there-CDCrel-1 may regulate the functioning of synaptic vesi-
cles, such as transport and release, and it is possible fore may accumulate in cells with reduced parkin ac-
tivity.that the increased abundance of this protein due to the
impairment of parkin may reduce synaptic release, but A more diverse role of parkin is suggested by its in-
creased expression following cellular stress associatedthis possibility remains to be evaluated.
Synphilin-1, which was identified and cloned as an with the accumulation of unfolded proteins (Imai et al.,
2000). Parkin can assist in the removal of misfolded-syn-interacting protein, also is a substrate for parkin-
targeted ubiquitination (Chung et al., 2001). The function proteins in the endoplasmic reticulum (ER), as demon-
strated for a homolog of endothelin receptor type B,of synphilin-1 is unknown, but it is present in LBs, and
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Klein, C., Pramstaller, P.P., Kis, B., Page, C.C., Kann, M., Leung, J.,renamed “Pael-R” (Parkin-associated endothelin recep-
Woodward, H., Castellan, C.C., Scherer, M., Vieregge, P., et al.tor-like receptor) (Imai et al., 2001). The ubiquitination
(2000). Ann. Neurol. 48, 65–71.and proteasome-mediated degradation of Pael-R can
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E.,be modulated by parkin. Overexpression of parkin can
Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T., et al.
suppress cell death associated with ER stress (Imai et (1998). Nature 395, 451–452.
al., 2000) and the accumulation of misfolded Pael-R, Lucking, C.B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G.,
which can be toxic to cells (Imai et al., 2001). The ER- Gasser, T., Harhangi, B.S., Meco, G., Denefle, P., Wood, N.W., et
resident E2 proteins UBC6 and UBC7 act with parkin al. (2000). N. Engl. J. Med. 342, 1560–1567.
to target Pael-R for degradation. Consistent with this Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori,
Y., Miyake, T., Suda, K., and Mizuno, Y. (1998). Neurology 51,function of parkin, there is an increase in detergent-
890–892.insoluble, presumably misfolded, Pael-R in the brains
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A.,of AR-JP patients. Pael-R is widely expressed in the
Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997).brain, predominantly in oligodendrocytes, but it is also
Science 276, 2045–2047.expressed at exceptionally high levels in tyrosine hy-
Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minos-droxylase-expressing neurons of the SN, perhaps con-
hima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., and Suzuki, T.
tributing to the selective vulnerability of these neurons (2000). Nat. Genet. 25, 302–305.
in AR-JP.
Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trock-
Dopaminergic nigral neurons may also be more vul- enbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S., and Selkoe,
nerable because of their intrinsic exposure to oxidative D.J. (2001). Science 293, 263–269.
stress that may result in protein damage and misfolding. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L., and Daw-
Parkin is widely expressed throughout the neuroaxis, son, T.M. (2000). Proc. Natl. Acad. Sci. USA 97, 13354–13359.
and it is possible that it can also be sequestered into
other types of pathological inclusions that share struc-
tural similarities to nigral LBs. The redistribution of par-
kin or other E3 ligases into proteinaceous inclusions
may be a common pathological mechanism.
The identification and characterization of defective
genes involved in the inherited forms of PD revealed
some of the primary causes of these disorders, but they
also provide insights into the biochemical pathways that
may also be involved in the sporadic forms of the dis-
ease. The wide range in the age of presentation, even in
some patients with the same gene defect, suggests that
other contributors, either modulatory genes or environ-
mental factors, are involved in the pathobiology of PD.
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